Hostname: page-component-7479d7b7d-k7p5g Total loading time: 0 Render date: 2024-07-10T21:10:09.287Z Has data issue: false hasContentIssue false
  • English
  • Français

Antihypertensive drugs and depression

Published online by Cambridge University Press:  09 July 2009

R. P. Snaith  and
M. McCoubrie
R. P. Snaith
Affiliation:
Stanley Royd Hospital, Wakefield, and the Hebden Bridge Group Practice, Yorkshire
M. McCoubrie
Affiliation:
Stanley Royd Hospital, Wakefield, and the Hebden Bridge Group Practice, Yorkshire
Get access Rights & Permissions [Opens in a new window]

Sysnopsis

The introduction of reserpine into western medical practice led to an outbreak of iatrogenic depression. It also stimulated research into the fundamental biochemical errors underlying depressive illness. In view of this historical incident it is surprising that other drugs used in the treatment of hypertension, especially those producing their therapeutic effects by a similar mechanism to reserpine, have not been more critically evaluated. This field of research calls for valid self-rating instruments in order to survey a large population. Using this method, it was found that there was no evidence of a relation between the administration of methyldopa or other drugs and depressive illness. These findings are an indication that adverse psychiatric effects of drugs for hypertension, and methyldopa in particular, may be less common than is sometimes supposed. It is concluded that the matter should be clarified by a careful prospective study.

Type
Research Article
Information
Psychological Medicine , Volume 4 , Issue 4 , November 1974 , pp. 393 - 398
Copyright
Copyright © Cambridge University Press 1974

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

British Medical Journal (1966). Methyldopa in hypertension. 1, 119–20.Google Scholar
Bulpitt, C. J., and Dollery, C. T. (1973). Side effects of hypotensive agents evaluated by a self-administered questionnaire. British Medical Journal, 3, 485–90.CrossRefGoogle ScholarPubMed
Dollery, C. T. (1965). Methyldopa in the treatment of hypertension. Progress in Cardiovascular Diseases, 8, 278–289.CrossRefGoogle ScholarPubMed
Doyle, A. E., and Smirk, F. H. (1954). Hypotensive action of reserpine. Lancet, 1, 1096–1097.CrossRefGoogle Scholar
Freis, E. D. (1954). Mental depression in hypertensive patients treated for long periods with large doses of reserpine. New England Journal of Medicine, 251, 1006–1008.CrossRefGoogle ScholarPubMed
Gibbons, J. L. (1968). Biochemistry of depressive illness. In Recent Development in Affective Disorders., pp. 55–64. Edited by A. Coppen and A. Walk. British Journal of Psychiatry, Special Publication No. 2.Google Scholar
Hamilton, Max (1965). Computer programmes for the medical man: a solution. British Medical Journal, 2, 1048–1050.CrossRefGoogle ScholarPubMed
Hamilton, M. (1968). Some aspects of the long-term treatment of severe hypertension with methyldopa. Postgraduate Medical Journal, 44, 66–69.CrossRefGoogle ScholarPubMed
Hamilton, M., and Kopelman, H. (1963). Treatment of severe hypertension with methyldopa. British Medical Journal, 1, 151–155.CrossRefGoogle ScholarPubMed
Heffernan, A., Carty, A., O'Malley, K., and Bugler, J. (1971). A within-patient comparison of debrisoquine and methyldopa in hypertension. British Medical Journal, 1, 75–78.CrossRefGoogle ScholarPubMed
Johnson, P., Kitchin, A. H., Lowther, C. P., and Turner, R. W. D. (1966). Treatment of hypertension with methyldopa. British Medical Journal, 1, 133–137.CrossRefGoogle ScholarPubMed
Lauwers, P., Verstraete, M., and Joossens, J. V. (1963). Methyldopa in the treatment of hypertension. British Medical Journal, 1, 295–300.CrossRefGoogle ScholarPubMed
Locket, S. (1955). Oral preparations of Rauwolfia serpentina in treatment of essential hypertension. British Medical Journal, 1, 809–813.CrossRefGoogle ScholarPubMed
Muller, J. C., Pryor, W. W., Gibbons, J. E., and Orgain, E. S. (1955). Depression and anxiety occurring during Rauwolfia therapy. Journal of the American Medical Association, 159, 836–839.CrossRefGoogle ScholarPubMed
Oates, J. A., Seligmann, A. W., Clark, M. A., Rousseau, P., and Lee, R. E. (1965). The relative efficacy of guanethidine, methyldopa and pargyline as antihypertensive agents. New England Journal of Medicine, 273, 729–734.CrossRefGoogle ScholarPubMed
Overall, J. E., and Klett, C. J. (1972). Applied Multivariate Analysis. McGraw-Hill: New York.Google Scholar
Pletscher, A., Shore, P. A., and Brodie, B. B. (1956). Serotonin as a mediator of reserpine action in the brain. Journal of Pharmacology and Experimental Therapeutics, 116, 84–89.Google Scholar
Prichard, B. N. C., Johnston, A. W., Hill, I. P., and Rosenheim, M. L. (1968). Bethanidine, guanethidine, and methyldopa in the treatment of hypertension: a withinpatient comparison. British Medical Journal, 1, 135–144.CrossRefGoogle ScholarPubMed
Rao, C. R. (1952). Advanced Statistical Methods in Biometric Research, pp. 221–235. Wiley: New York.Google Scholar
Schildkraut, J. J. (1965). The catecholamine hypothesis of affective disorders: a review of supporting evidence. American Journal of Psychiatry, 122, 509–522.CrossRefGoogle ScholarPubMed
Simpson, F. O., and Waal-Manning, H. J. (1971). Hypertension and depression: interrelated problems in therapy. Journal of the Royal College of Physicians, London, 6, 14–24.Google ScholarPubMed
SirSmirk, H. (1963). Hypotensive action of methyldopa. British Medical Journal, 1, 146–151.CrossRefGoogle ScholarPubMed
Snaith, R. P., Ahmed, S. N., Mehta, S., and Hamilton, M. (1971). The assessment of the severity of primary depressive illness. Wakefield self-assessment depression inventory. Psychological Medicine, 1, 143–149.CrossRefGoogle ScholarPubMed
Sourkes, T. L. (1965). The action of α-methyldopa in the brain. British Medical Bulletin, 21, 66–69.CrossRefGoogle Scholar
Turner, R. W. D. (1962). Choice of drug in the treatment of hypertension. Proceedings of the Royal Society of Medicine 55, 280–283.Google ScholarPubMed